News & Updates

Several disease-modifying therapies (DMTs) for multiple sclerosis (MS) do not pose an increased risk of cancer, a study has shown.

Use of opioids in the long term leads to shorter length of stay (LOS) and reduced inpatient mortality among patients hospitalized with nonmetastatic colorectal cancer (CRC), results of a study have shown. However, patients with cancer-related complications endure longer LOS and higher mortality than those admitted without such morbidities.

Both individualized counselling (IC) and pamphlets have improved the uptake of influenza vaccination, but IC does not appear to be superior to pamphlets alone at improving vaccine acceptance, according to a Singapore study.

In a phase II study, the novel oral HIF*-2α inhibitor belzutifan showed promise for individuals with renal cell carcinoma (RCC) associated with von Hippel-Lindau (VHL) disease, a rare autosomal dominant hereditary disease associated with benign and malignant neoplasms, including clear-cell RCC, pancreatic neuroendocrine tumours, and CNS** and retinal hemangioblastomas.

The combination of cabozantinib and atezolizumab in the first-line setting significantly improved progression-free survival (PFS) compared with sorafenib in patients with advanced hepatocellular carcinoma (HCC), according to results of the phase III COSMIC-312 trial presented at ESMO Asia 2021.

Individuals with risk factors for heart failure (HF) may have an increased risk of developing the condition if they are aspirin users, results of the HOMAGE* study showed.